OPINION | REGENERATIVE MEDICINE |
marketplace, the results do not show overnight, taking a few months for the full effects to emerge. This can cause problems, as most patients want immediate results. Furthermore, PRP is not an FDA-approved treatment for cosmetics. The treatment came to the market in orthopaedics and sport medicine in 2002 and was FDA-cleared in 2006 for orthopaedics only; it doesnÕ t have an aesthetic indication in the US. However, the treatment is CE-approved. One of the key actors in the PRP market
is Selphyl Aesthetic Factors, which manufactures the Selphyl system ® especially in the US, Japan, Middle East and the UK ® and has around 300 customers in the US alone since its introduction in 2010. Sanjay Batra, Chief Executive of Aesthetic Factors, says that Selphyl is growing and will do well,
especially with younger patients who need a more subtle rejuvenation; itÕs a great treatment to correct the early signs of ageing. In the skincare industry, the natural
market is growing quickly, so it is easy to imagine that lighter, less synthetic and more natural approaches could bring to the cosmetic market newcomers who would never consider having a botulinum toxin injection, but could be seduced by the regenerative medicine approach. Batra says that the impact of
regenerative medicine within the cosmetic market can also be seen in another field that is rapidly gaining ground: fat grafting.
Fat grafting In July 2012 BatraÕs company acquired Viafill from the Lipose Corporation ® a rapidly growing autologous adipose fat transfer treatment. Driven by an interest in natural alternatives to synthetic fillers, the fat grafting market has grown considerably in recent years. According to the American Society of Plastic Surgery (ASPS) Procedural Statistics, fat grafting procedures in the US have increased by 19% in 2011 from 2010, with more than 68 000 procedures performed annually. Fat grafting isnÕt new, but more
doctors are using advanced techniques for harvesting, processing and delivering fat grafts to achieve better survival and longevity of the grafted fat. One leading actor on the market is Cytori with PureGraft. Once the adipose tissue is removed, it only takes 15 minutes for PureGraft to boost the fat by selectively draining the tumescent fluid, free lipids, blood cells, and excessive fluid from the graft. It is then ready for reinjection. One of
62 ❚
the main advantages of Viafill and PureGraft is that they are FDA cleared and give physicians an eff ecti v e , convenient, and cost-effective method to
January/February 2013 |
prime-journal.com
process the adipose tissue intended for immediate re-implantation.
A challenge to dermal fillers LAVIV (azficel-T) from Fibrocell is the latest launch also completely based on rejuvenative medicine to challenge synthetic dermal fillers to reverse the clock. LAVIV is a treatment Ômade especially
for you from your own skin cellsÕ . It works by isolating, purifying and multiplying a
According to the ASPS Procedural
Statistics, fat grafting procedures in the US have increased by 19%, with more than 68000 procedures performed annually.
patientÕs own collagen-producing fibroblast cells to smooth out wrinkles. It involves taking a sample of skin cells called fibroblasts, which make collagen, from behind the clientÕs ear. The sample is sent to the companyÕs laboratory, where the fibroblasts are multiplied in cell culture; a process that takes 11–22 weeks. The cells are then sent back to the doctor, who injects them into the nasolabial folds. A series of three treatments spaced every 3–4 weeks are recommended. The treatment costs around $2500. According to Fibrocell Science
Chairman and CEO David Pernock, LAVIV is the first and only personalised cell treatment approved by the FDA for aesthetic use, and one of only two personalised cell treatments approved in the last decade. LAVIV has been FDA-approved for improvement in the appearance of moderate to severe nasolabial lines. Pernock anticipates supplemental indications for LAVIV for the treatment of acne scars, fine lines and wrinkles around the eyes, lips, and d• colletage, and the treatment of restrictive burn scars and vocal cord scarring. Since FDA approval in 2011, over 750 board-certified dermatologists and plastic surgeons have participated in the Fibrocell-approved training programme and can now offer LAVIV to their patients. As reported in a press release distributed by Fibrocell Science on 16 July 2012, more than 700 LAVIV biopsies have been scheduled by physicians for their patients since the US launch in October 2011.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76